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ABSTRACT
Background and aims Tuberculosis (TB) patients who quit smoking have much better disease outcomes than those
who continue to smoke. In general populations, behavioural support combined with pharmacotherapy is the most effec-
tive strategy in helping people to quit. However, there is no evidence for the effectiveness of this strategy in TB patients who
smoke. We will assess the safety, effectiveness and cost-effectiveness of cytisine—a low-cost plant-derived nicotine
substitute—for smoking cessation in TB patients compared with placebo, over and above brief behavioural support.
Design Two-arm, parallel, double-blind, placebo-controlled, multi-centre (30 sites in Bangladesh and Pakistan),
individually randomized trial. Setting TB treatment centres integrated into public health care systems in
Bangladesh and Pakistan. Participants Newly diagnosed (in the last 4 weeks) adult pulmonary TB patients who
are daily smokers (with or without dual smokeless tobacco use) and are interested in quitting (n = 2388).
Measurements The primary outcome measure is biochemically veriﬁed continuous abstinence from smoking at
6 months post-randomization, assessed using Russell Standard criteria. The secondary outcome measures include
continuous abstinence at 12 months, lapses and relapses; clinical TB outcomes; nicotine dependency and withdrawal;
and adverse events. Comments This is the ﬁrst smoking cessation trial of cytisine in low- and middle-income coun-
tries evaluating both cessation and TB outcomes. If found effective, cytisine could become the most affordable cessa-
tion intervention to help TB patients who smoke.
Keywords Bangladesh, cytisine, low- and-middle income countries, Pakistan, placebo-controlled randomized trial,
smoking cessation, tobacco cessation, tuberculosis.
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INTRODUCTION
Tuberculosis (TB) is a widespread and, in many cases, fatal
infectious disease. Approximately 85% of TB deaths occur
in the low- and middle-income countries (LMICs) in
African and the South-East Asian regions [1]. Evidence
suggests that smoking increases the risk of developing TB
disease [2–4] and leads to poorer outcomes in those TB
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patients who continue to smoke [3,5]. Of the 10.4 million
incident cases of TB in 2016, an estimated 0.8millionwere
attributable to smoking [1].
Newly diagnosed TB patients experience high levels of
anxiety, including fear of death and worries about infect-
ing others. This provides a ‘teachable moment’ that health
professionals can use to offer smoking cessation advice [6].
‘Teachable moments’ are conceptualized as events or sets
of circumstances that can lead patients to alter their
health behaviour positively [7]. Moreover, the potential
health beneﬁts of cessation are greater among TB patients
than among other smokers, as most of the tobacco-
induced immunological abnormalities in TB patients re-
verse within 6 weeks of quitting [8]. It therefore makes
sense to offer smoking cessation to TB patients who smoke
as part of routine care, although this opportunity is rarely
taken [9,10].
There is substantial evidence on the effectiveness of be-
havioural support (BS) and a range of pharmacotherapies
available for smoking cessation [11–14]. While these med-
ications, particularly nicotine replacement therapy (NRT)
and varenicline, are widely recommended, their costs pro-
hibit their use in LMICs. Cytisine—a plant-derived pharma-
cotherapy (manufactured as Tabex and Desmoxan)—has
recently gained recognition as a safe, efﬁcacious and afford-
able cessation aid [14,15]. Although cytisine is not licensed
in most countries outside eastern Europe [16,17], recent
studies [18,19] highlight its potential for use in LMICs
[14]. Particularly attractive is its lower cost (US$20–30
for 25 days) in comparison to NRT (US$112–685 for
8–10 weeks) and varenicline (US$474–501 for 12 weeks)
[20]. Cytisine was therefore chosen as a suitable medica-
tion to trial as part of a project called ‘TB and Tobacco’—
a European Union (EU)-funded study of tobacco cessation
in TB patients in South Asia.
The TB and Tobacco study investigates an innovative
approach to improve lung health in LMICs by integrating
inexpensive tobacco cessation strategies of proven efﬁcacy
into TB programmes. The project has two goals: (i) the
effectiveness goal—the TB and Tobacco trial; and (ii) the
implementation goal—BS implementation, its process and
context evaluation. This protocol focuses on the effective-
ness goal.
The primary aim of this trial is to evaluate the effective-
ness and cost-effectiveness of cytisine for smoking cessation
among TB patients. Secondary aims include assessment of
its effectiveness and cost-effectiveness in improving TB
outcomes; differential effect by the form of tobacco used;
effect moderators: TB severity, socio-economic status
(SES), gender and age; adverse effects; nicotine depen-
dency, withdrawals; and process of delivery. An overview
of all objectives is listed in Table 1.
METHODS
Design
This is a phase III, double-blind, individually randomized,
parallel-group placebo-controlled trial. Participants will
receive random allocation in a 1 : 1 ratio to cytisine or
matching placebo treatment. Figure 1 illustrates the TB
and Tobacco trial ﬂow-chart.
Ethics approval
The trial was granted ethics approval by the Health Sci-
ences Research Governance Committee (HSRGC) at the
University of York, UK, by the National Bioethics
Committee, Pakistan Medical Research Council (Ref: no.
4–87/16/NBC-200 Part-B/RDC/4197) and by the
National Research Ethics Committee, Bangladesh Medical
Table 1 TB and Tobacco trial objectives.
Primary objective
(a) To evaluate the effectiveness and cost-effectiveness of cytisine for smoking cessation among tuberculosis (TB) patients who smoke on
a daily basis
Secondary objectives
(b) To assess the effectiveness and cost-effectiveness of cytisine in improving the clinical outcomes of TB patients who smoke tobacco
(c) To assess any differences in the effectiveness by the form of tobacco used (tobacco smoking only versus a combination of smoking and
smokeless tobacco)
(d) To assess any differences in the effect across different TB severity groups, high and low socio-economic status (SES), gender and age
subgroups
(e) To translate for use in the target population and assess psychometric properties (validity and reliability) of the Mood and Physical
Symptoms Scale (MPSS) for the assessment of withdrawal symptoms, and the Strength of Urges to Smoke (SUTS) for the assessment
of nicotine dependency
(f) To assess adverse effects of cytisine in the target population
(g) To assess all relevant components of the design and delivery of the smoking cessation programme as part of a process evaluation
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Research Council (Ref: BMRC/NREC/2016–2019/1475).
As cytisine is not licensed for use in either country,
approvals were obtained from the Drug Regulatory
Authority of Pakistan (1 December 2016) and the Director-
ate General of Drug Administration in Bangladesh (21
March 2017).
Participants
Participants will be newly diagnosed (within the last
4 weeks) adult pulmonary TB patients who smoke (with
or without dual smokeless tobacco use) on a daily basis,
wish to quit and are able to provide consent. Table 2 pre-
sents participants’ eligibility criteria.
Participants will not receive ﬁnancial incentives
except nominal travel costs for any follow-up visits that fall
outside routine TB care. The trial will be conducted at 17
sites in Bangladesh and 13 in Pakistan. Sites are designated
TB treatment centres run by the respective National TB
control Programmes (NTP). Supporting information,
Appendix S1 lists the trial sites.
Interventions
All trial participants will receive brief BS for smoking cessa-
tion integrated within the more broad advice offered to TB
patients to manage their TB and adhere to TB medication.
Two face-to-face BS sessions will be delivered at days 0 and
5 (for 10minutes and 5minutes, respectively). Further en-
couragement and support is offered, if needed, at the week
5 visit. BS materials have been translated and adapted to
the local context in Bangladesh and Pakistan. The ﬁndings
relating to the implementation goal of the TB and Tobacco
project will inform further adaptation of the BS, to enable
Figure 1 TB and Tobacco trial ﬂow-chart
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scale-up and sustainable delivery within National TB
Programmes (see Supporting information, Appendix S2
and Appendix S3 for details on BS).
Randomized patients will receive either cytisine (as
Desmoxan) (active arm) or matching placebo (control
arm) in their Investigational Medicinal Product (IMP),
which ismanufactured as 1.5mg hard capsules for oral ad-
ministration, with a shelf-life of 2 years. Patients receive
7 days’ IMPon the dayof enrolment and are expected to re-
turn on the ﬁfth day (±2 days), coinciding with their quit
date, when they are dispensed another 18 days’ supply by
the study researcher.
Cytisine
Cytisine, a partial agonist of nicotinic acetylcholine recep-
tors, is pharmacologically similar to varenicline (Chantix).
With a half-life of 4.8 hours, cytisine is eliminated rapidly
from the body [20]. The standard regimen is a 25-day
course, reducing gradually from six capsules a day to one
capsule on the last day by the end of the treatment period,
with a quit date set for day 5 [15]. Table 3 presents the
dosing schedule for the cytisine.
Placebo
Patients in the control arm will receive the placebo in ex-
actly the same manner as cytisine. A checking exercise
was carried out using paired samples of capsules to ensure
that placebo pills were unrecognizable. Blinded York Trials
Unit staff could not distinguish between placebo and active
pills based on their appearance, smell or taste.
Outcomes
Patients will have assessments on days 0 (baseline) and 5,
weeks 5, 9 and 12 and months 6 and 12. These time-
points, except day 5 and month 12, were chosen to corre-
spond with routine TB care visits. The day 5 visit is to
Table 2 Patient eligibility criteria.
Inclusion criteria
(a) Age at least 15 years in Pakistan and 18 years in Bangladesh (deﬁnitions of adult TB patients in the two countries)
(b) Able to provide consent
(c) Diagnosed with pulmonary TB (smear-positive or -negative) in the last 4 weeks
(d) Currently smokes tobacco on a daily basis (with or without smokeless tobacco use)
(e) Willing to quit tobacco use
Exclusion criteria
(a) Re-treatment TB, MDR TB, miliary or extra-pulmonary TB
(b) Currently receiving streptomycin (category II anti-TB medication) and/or PASAa
(c) Currently using any pharmacotherapy for tobacco dependence
Cytisine contraindications:
(d) Pregnant, lactating or planning to become pregnant
(e) Had myocardial infarction, stroke or an attack of severe angina within the previous 2 weeks
(f) Uncontrolled high blood pressure despite being on medication
(g) Severe renal impairment (requiring dialysis)
(h) Suffering from schizophrenia or known to be diagnosed with epilepsy
TB = tuberculosis; PASA = para amino salicylic acid; MDR =multi-drug-resistant. aUsing cytisine with anti-TB medicines (PASA, streptomycin) reduces stim-
ulant action of cytisine [39].
Table 3 Dosing schedule of cytisine and packing details.
Day of treatment
Intake interval
(1–6 capsules daily during a
period of 12 waking hours)
Total daily capsules
(number included in each packet)
Days 1–3 1 capsule every 2 hours 6 capsules daily (6 × 3 = 18 capsules per packet)
Days 4–7 1 capsule every 2.5 hours 5 capsules daily (5 × 4 = 20 capsules per packet)
Days 8–12 1 capsule every 2.5 hours 5 capsules daily (5 × 5 = 25 capsules per packet)
Days 13–16 1 capsule every 3 hours 4 capsules daily (4 × 4 = 16 capsules per packet)
Days 17–20 1 capsule every 4 hours 3 capsules daily (3 × 4 = 12 capsules per packet)
Days 21–24 1 capsule every 6 hours 2 capsules daily (2 × 4 = 8 capsules per packet)
Day 25 1 capsule on the last day 1 capsule on the last day
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monitor for any adverse drug reaction and the month 12
visit is to assess longer-term smoking cessation and any
TB relapses. Table 4 provides the schedule for trial partici-
pants from initial eligibility screening, dispensing of IMP
and the data collection/assessments.
Primary outcome measure
The primary outcome is biochemically veriﬁed continuous
smoking abstinence at 6 months post-randomization, as
per Russell Standard [21]; self-report of not using more
than ﬁve cigarettes/bidis/water pipe sessions/chewing
tobacco products from the quit date (5 ± 2 days) supported
by a negative exhaled carbon monoxide [CO< 10 parts per
million (p.p.m.)] test at 6 months, using a Micro MC02 CO
Monitor (CareFusion UK Ltd, Wokingham, UK). In con-
comitant smokeless tobacco users, instead of CO, a cotinine
dipstick test (OneStep Urine Test Strip, sensitivity
200 ng/ml, supplied by Home Health UK, Bushey, UK) will
be used for biochemical veriﬁcation of abstinence. An ele-
vated CO or cotinine level will always take precedence over
the patient’s self-reported abstinence. In the analysis, pa-
tients will be considered smokers if their smoking status
could not be determined.
Although smoking status is assessed at both 6 and at
12 months’ time-points, in the interest of better retention
rates primary outcome is measured at 6 months.
Secondary outcome measures
Abstinence, lapses and relapses. Abstinence, lapses and re-
lapses comprise: continuous abstinence at 12 months
(same deﬁnition as for primary outcome at 6 months);
point abstinence, deﬁned as a self-report of not using
tobacco in the previous 7 days at weeks 5 and 12 and at
months 6 and 12 (abstinence is veriﬁed biochemically at
months 6 and 12 only). In addition, early-lapse, late-lapse,
early-relapse and late-relapse will be assessed according to
the deﬁnitions presented in Table 5.
TB outcomes. Assessment for the impact of smoking cessa-
tion on TB outcomes includes clinical TB score [22–24];
sputum conversion results; chest X-ray grading (normal,
minimal, moderately advanced or far advanced TB) [25];
adherence to TB treatment; and standard TB treatment
outcomes (success, failure, default, relapse or death). The
researchers will assess signs and symptoms for TB score
(supported by the clinical team), while routine reporting
on TB cards/registers maintained by the TB programme
will provide the remaining TB outcomes. Table 6 presents
the deﬁnitions of the TB outcomes.
Nicotine dependency. Assessment of nicotine dependency
includes translated versions of the Mood and Physical
Symptoms Scale (MPSS) [27], the Strength of Urges To
Table 4 Schedule of enrolment and follow-up assessments for TB and Tobacco trial.
Assessment
Study period
Time-point Day 0 Day 5
Week 5
(day 35)
Week 9
(day 63)
Week 12
(day 84)
Month 6
(week 25)
Month 12
(week 52)
Allowed variation in days /+2 days /+5 days
Eligibility screen x
Informed consent x
Randomization x
Tobacco use (self-reported) x x x x x
Socio-demographic historya x
Tobacco use and quit historyb x
Nicotine dependencec x x x x x
Economic outcomes x x x
Process outcomes x x
Tobacco use (biochemical measures) x x
Study medication dispensing x (for 7 days) x (for 18 days)
Medication adherence x x
Adverse events review (checklist) x x x
Clinical TB score x x x x x x
TB sputum conversion x x x x x
TB chest X-ray grading x x x x
TB treatment adherence x x x
TB treatment outcomes x x
TB = tuberculosis. aSocio-demographic history includes: age, gender, marital status, household assets, education, work status; btobacco use and quit history
includes: initiation, duration, type, frequency and quantity of tobacco use, smoking restrictions inside homes, number of quit attempts, last quit attempt and
duration of longest quit attempt; cnicotine dependence includes: Mood and Physical Symptoms Scale, Strength of Urges To Smoke scale and Heaviness of
Tobacco Index.
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Smoke (SUTS) scale [26] and the Heaviness of Smoking
Index (HSI) [28,29] in Bangla and Urdu.
Adverse events. Table 7 presents deﬁnitions of adverse
events (AEs), which will be collected up to week 9, and
self-reports recorded on the ‘AEs review’ checklist in the pa-
tient case-report form that is compiled from the summary
of product characteristics for Desmoxan and previous rele-
vant randomized controlled trials (RCT) [16,19,30,31].
The checklist includes symptoms relating to possible
cytisine side effects: nausea, diarrhoea, dry mouth, epigas-
tric pain, headache, insomnia, abnormal dreams, irritabil-
ity, anxiety, tachycardia and musculoskeletal pain. A
clinical review will be required for patients reporting any
Table 5 Smoking cessation outcomes: primary and secondary measures.
Outcome Deﬁnition
Primary outcome measure:
Continuous abstinence
(at 6 months)
Self-report of not using more than ﬁve cigarettes/bidis/water pipe sessions/chewing tobacco
products from the quit date (5 +/ 2 days) to the reporting date, supported by a negative
biochemical test at 6 months
Secondary outcome measures:
Continuous abstinence
(at 12 months)
Self-report of not using more than ﬁve cigarettes/bidis/water pipe sessions/chewing tobacco
products from the quit date (5 +/ 2 days) to the reporting date, supported by a negative
biochemical test at 12 months
Point abstinence Self-report of not using tobacco in the previous 7 days, assessed at weeks 5 and 12, and at
months 6 and 12
Early-lapse Self-report of tobacco use (even once) after the quit date but having point abstinence
at week 5
Late-lapse Self-report of tobacco use (even once) between weeks 5 and 12 but showing point abstinence
at weeks 5 and 12
Early-relapse Abstinence at week 5 but a self-report of tobacco use by week 12
Late-relapse Abstinence at weeks 5 and 12 but a self-report of tobacco use by month 6
Table 6 TB outcomes.
TB score TB score consists of the following clinical signs and symptoms of TB: cough, chest pain, dyspnoea,
anaemia, BMI < 18 kg/m
2
, MUAC < 220 mm. Each of the six clinical variables contributes 1 point,
and BMI and MUAC contribute an extra point if < 16 kg/m
2
and < 200 mm, respectively, hence
the maximum score of 8. Assessments for TB score are at day 0, weeks 5, 9 and 12 and months 6
and 12. The TB score will be categorized into four severity classes (I–IV): SC I < 2 points, SC II 2–3
points, SC III 4–7 points and SC IV > 7 points [22]
Sputum conversion Sputum conversion results obtained at weeks 5 and 9 and at months 6 and 12, from routine TB
laboratory testing
Chest X-ray grading Chest X-rays reports obtained at day 0, week 9 and months 6 and 12 graded according to the
National Tuberculosis Association of the USA grades by a senior radiologist will be categorized into
four grades as 0 (normal), 1 (mild), 2 (moderate) and 3 (far advanced TB) [40]
Treatment adherence TB patient’s medication logs (for anti-TB medication) consulted from routine TB cards will provide
adherence assessments at day 0, week 9 and month 6
Programme outcomes Programme outcomes, as deﬁned [41] below, recorded from routine TB registers at month 6.
Additionally, relapse assessed at month 12 follow-up
Cured: ‘A patient who was initially smear-positive and who was smear negative in the last month of
treatment (at month 6) and on at least one previous occasion’
Completed treatment: ‘A patient who completed treatment (at month 6) but did not meet the criteria
for cure or treatment failure’
Treatment failure: ‘A patient who was initially smear-positive and who remained smear-positive at
month 5 or later during treatment’
Defaulted: ‘A patient whose treatment was interrupted for 2 consecutive months or more’
Died: ‘A patient who died from any cause during treatment’
Relapsed: ‘A patient who was previously treated for TB, was declared cured or treatment completed
at the end of his most recent course of treatment, and is now diagnosed with a recurrent episode
of TB (either a true relapse or a new episode of TB caused by re-infection)’
TB = tuberculosis; BMI = body mass index; MUAC = mid upper arm circumference; SC = severity class.
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moderate to severe symptoms, classiﬁed using the Com-
mon Terminology Criteria for Adverse Events (CTCAE)
[32]. A site-designated clinician, trained in study-related
AEs, will review and determine the severity and relation-
ship of the event to the study treatment.
The researcher at each site will notify all serious ad-
verse events to the country coordinating ofﬁce within
24 hours of becoming aware of an event, who will in turn
notify the York trial teamwithin (a further) 24 hours. Med-
ically qualiﬁed staff at the country coordinating ofﬁce will
conﬁrm ‘causality’ and ‘expectedness’ and code these
events using the Medical Dictionary for Regulatory Activi-
ties (MedDRA) [33].
Adherence. Adherence will be monitored using a question-
naire at day 5 and each subsequent follow-up appoint-
ment, as well as by counting empty cells in the blister
packets (day 5 and week 5). Dosing schedule cards will
be provided to help to maximize adherence.
Process evaluation. A mixed-methods process evaluation
will assess reach, dose received, dose delivered and ﬁdelity
for trial and BS components; the protocol is submitted sep-
arately for publication.
Sample size
The sample size is based on known cessation rates for
BS and previously observed group differences using
cytisine. The Action for Stopping Smoking In Suspected
TB (ASSIST) trial (based on 1955 patients in Pakistan)
reported that 41% of regular smokers with presumptive
TB sustained biochemically veriﬁed smoking cessation
at 6 months after random allocation to BS [34].
Previous RCTs of cytisine have shown increases of
6–7% (differences in absolute percentages) for sustained
cessation [16,19,30]. To detect an increase of 6% in
the 6-month abstinence rate for the addition of cytisine
to BS, from 41 to 47% with 80% power, testing at the
5% signiﬁcance level, requires primary outcome data
for a total of 2148 participants (1074 in each arm).
The ASSIST trial reported missing primary outcome data
on 5.5% of participants. Assuming a more conservative
attrition rate of 10% gives a target recruitment of
2388 participants (1194 in each arm).
Randomization
Allocation to the trial arms is by pre-prepared block ran-
domization lists for each country, generated by the trial
statistician. IMP packs are labelled sequentially in their
randomized order and distributed to trial sites in batches.
Once a patient has consented to participate, the researcher
at the site calls the country coordinating ofﬁce to obtain the
patient’s allocated trial number and conﬁrm the next IMP
pack number in the sequence to dispense to the patient.
Blinding
Patients, clinical team and researchers will remain blind to
treatment allocation. To ensure double-blinding, IMP
packs appear identical and only the code-break envelopes
prepared separately for each trial number could ascertain
treatment allocation. In an emergency, any request to
un-blind must be authorized by a clinician or senior trial
staff. Each country coordinating ofﬁce will be contactable
Table 7 Deﬁnitions of adverse events.
Term Deﬁnition
Adverse event (AE) Any untoward medical occurrence in a patient to whom an IMP has been
administered including occurrences that are not necessarily caused by or
related to that product
Adverse reaction (AR) Any untoward and unintended response to an IMP related to any
dose administered
Unexpected adverse reaction (UAR) An adverse reaction, the nature or severity of which is not consistent with
the information about the medicinal product in question set out in the SPC
for that product, patient information leaﬂet, IB or protocol
Serious adverse event (SAE) or serious
adverse reaction (SAR) or suspected
unexpected serious adverse reaction
(SUSAR)
Respectively any adverse event, adverse reaction or unexpected adverse
reaction that:
▪ Results in death
▪ Is life-threateninga
▪ Requires hospitalization or prolongation of existing hospitalizationb
▪ Results in persistent or signiﬁcant disability or incapacity
▪ Consists of a congenital anomaly or birth defect
aThe term life-threatening in the deﬁnition of a serious event refers to an event inwhich the patient is at risk of death at the time of the event; it does not refer to
an event that hypothetically might cause death if it were more severe, bhospitalization is deﬁned as an in-patient admission, regardless of length of stay, even if
the hospitalization is a precautionarymeasure for continued observation. Hospitalizations for a pre-existing condition, that has not worsened or for an elective
procedure, do not constitute an SAE, for example, a silent myocardial infarction. IMP = Investigational Medicinal Product; SPC = Summary of Product Char-
acteristics; IB = Investigator Brochure.
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by in- and out-of-ofﬁce hours contact numbers; the
contacted staff will need to travel to the ofﬁce in order to
access the code-break envelopes and follow the procedure
for un-blinding as per manual of operations.
Statistical methods
Analyses will be based on intention-to-treat, analysing par-
ticipants in the arm towhich theywere randomized. Signif-
icance tests will be two-sided at the 5% level. Baseline
characteristics (see Table 4 for details) will be presented de-
scriptively to assess balance between cytisine and placebo
arms in terms of: (a) ecological factors at the TB treatment
centre level; and (b) individual factors at patient level.
Primary analysis
Missing primary outcome data will be treated as a negative
outcome, i.e. continuous smoking [21]. Agreement be-
tween self-reported and biochemically veriﬁed abstinence
will be reported by trial arm. The number and proportion
of abstinent patients will be reported by trial arm, and
group differences will be illustrated by the risk difference
and relative risk with associated 95% conﬁdence intervals
(CIs) and P-values. Abstinence rates will be compared be-
tween the active and the control arms using logistic regres-
sion. Trial sites will be included as a random effect using
robust standard errors.
Secondary outcomes analysis
The primary analysis will be repeated for the following sec-
ondary outcomes: continuous abstinence for 12 months,
point abstinence at weeks 5 and 12 and months 6 and
12, as well as early and late lapses and relapses (Table 5).
Point abstinence will be plotted over time. TB outcomes of
TB score, sputum conversion, X-ray assessment, treatment
adherence and programme outcomes, as well as with-
drawal and dependency as measured by MPSS and SUTS,
will be analysed using appropriate statistical models
for continuous or categorical data using all available
time-points.
The total number of AEs, the number of patients with
any AE and the number of AEs per patient will be reported
by trial arm. The number of patients with any AE will be
compared by χ2 test between arms.
Levels of adherence to study treatment will be pre-
sented descriptively [means and standard deviations
(SDs), as well as grouped as ≥ 80% (strong adherence),
< 80% but ≥ 50% (moderate adherence) and< 50% (poor
adherence)]. Compliers will be deﬁned as those having
taken any dose of medication on 80% or more of the pre-
scribed days. Patients with missing data at 5 weeks will
be assumed to be non-compliant with the trial regimen.
Sensitivity analyses
Sensitivity analyses will include: (i) primary analysis
adjusting for baseline level of dependence; (ii) primary
analysis adjusting for baseline level of dependence, age,
gender, form of tobacco use and any potentially inﬂuential
baseline variables for which chance imbalances between
groupsmay have been observed; and (iii) an appropriate re-
peat of the primary analysis that takes treatment adher-
ence into account.
Subgroup analyses
The primary logistic regression analysis will be repeated,
including a treatment × subgroup interaction for six sub-
groups, collected at baseline: (i) tobacco use (smoked only,
smoked and smokeless), (ii) gender (male, female), (iii) age
(< 40, ≥ 40), (iv) TB severity (I–IV), (v) SES (percentile
cut-off of a wealth index derived from education/
household assets/work status) and (vi) country
(Pakistan, Bangladesh). Abstinence rates, risk differences
and relative risk for each subgroup will be reported with
95% CIs. P-values for the interaction terms will be re-
ported; however, the trial is not powered to detect
interactions.
Cost-effectiveness analysis
In order to undertake a full cost-effectiveness analysis
(CEA), costs of the interventions and participants’ use of
wider health care (e.g. doctor visits, hospital attendances,
etc.) will be collected for both groups. Basic unit costs col-
lected alongside the trial will then be applied to complete
health-care cost proﬁles. The costs of patients’ TB-related
care will be included in the service-use questionnaires
and costs allocated accordingly. Two outcomes will be used
for the CEA; quitters (primary outcome) and quality-
adjusted life-years (QALYs), calculated from the EQ-5D-
5 L (a measure of health utility) collected during the trial
[35]. We will calculate incremental cost-effectiveness ra-
tios (ICER) combining treatment and wider health-care
costs with each outcome.
Bootstrapping techniques will be employed and cost-
effectiveness planes and cost-effectiveness acceptability
curves will be constructed to reﬂect any uncertainty in
the results and threshold. The CEA will demonstrate the
value for money of adding cytisine to BS from the perspec-
tive of the service provider (the public or voluntary sector).
We will also estimate the wider societal cost to patients,
with a supporting analysis presenting the costs to patients
incurred from out-of-pocket payments, productivity loss
and travel costs.
Oversight committees
Trial oversight committees include an Independent
Steering Committee (ISC), an independent Data
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Monitoring and Ethics Committee (DMEC) and the Trial
Management Team (TMG). Only the DMEC will have ac-
cess to the unblinded comparative data from the trial.
The study will be stopped, as guided by the ISC and DMEC,
if: (i) new literature indicates ﬁndings that can be applied to
this question in terms of beneﬁt or side effects. However,
early evidence of clear beneﬁt would not be a reason to halt
recruitment in the trial because data on TB outcomes
would still be useful for the full sample size. (ii) Reporting
of AEs indicates that review of the study protocol is re-
quired for the study medication.
Dissemination policy
Results will be disseminated to key stakeholders and pa-
tients in several ways. These include: open-access peer-
reviewed journal articles; presentation at key scientiﬁc
meetings; posting on the study website; feedback to trial
participants; press releases at collaborating universities.
We will explore non-academic routes to dissemination,
for example through the NTPs in Bangladesh and
Pakistan. The ﬁndings of the TB and Tobacco trial will be
made public (after academic publication), in accordance
with the requirements of the funder (EU) and Addiction
journal. We are committed to share our behavioural sup-
port intervention materials and the related training pack-
ages at the end of the study. Requests for access to data
and code will be reviewed by the study Chief Investigator
and conﬁrmed with the sponsor (University of York). The
criteria for authorship will be taken from the International
Committee of Medical Journal Editors [38].
Trial status
The current HSRGC approved protocol is version 3.0 (24
March 2017). This manuscript is a re-structured and
edited version of the current approved protocol, to comply
with the CONSORT reporting guidelines. The ﬁrst patient
was recruited into the trial on 06 June 2017 in Pakistan
and 22 July 2017 in Bangladesh. Recruitment is antici-
pated to be complete by the end of May 2018.
DISCUSSION
Our trial is innovative and important in several ways. To
our knowledge, this is the only pragmatic RCT investigat-
ing the safety, effectiveness and cost-effectiveness of
cytisine for smoking cessation in LMICs and in TB patients.
It is also, so far, the largest trial of cytisine in the world. De-
spite an overwhelming case for providing cessation support
to TB patients [36], this has generally not been conducted.
Lack of evidence on cheap and effective solutions has been
a signiﬁcant barrier. For those living in LMICs it may be
considered less expensive to continue smoking than to pur-
chase smoking cessation medications [19]. Cytisine, if
proven effective, can offer a cheaper alternative to other
cessation aids. Furthermore, because cytisine is a plant-
based medication, adherence may be better than with
synthetic products. It may ﬁt well with certain cultures
blending traditional approaches with western-style
medicine.
The current evidence on the effectiveness of smoking
cessation interventions, based on quit rates, has had lim-
ited success in convincing TB managers to include these
in routine TB care. Our trial will test the impact of smoking
cessation on TB outcomes—a key strength of this study.
This could provide leverage to include cessation within
routine TB care. Identifying cost-efﬁcient means to inﬂu-
ence TB and tobacco—the two converging epidemics—
could beneﬁt policy directions in the area [37].
Our trial is conducted in Pakistan and Bangladesh,
where smokeless tobacco use is common. With any efforts
towards encouraging people to quit smoking, there are al-
ways concerns that people may quit smoking but switch to
smokeless tobacco. A unique feature of this study is that it
can assess any substitution between smoking and smoke-
less tobacco.
The study’s results will need to be considered in the
light of some caveats, including some anticipated risks.
Trial participants’ adherence with the complicated dose
regimen of cytisine could be a potential issue.While wewill
assess adherence with cytisine using a number of self-
reported measures, we are concerned that participating
TB patients may ﬁnd it challenging to take cytisine (with
its frequent dosing schedule) along with their TB treat-
ment. Given that ours is an effectiveness trial, any attempts
to increase adherence are limited to what is feasible in the
real world. It is also important to acknowledge that if BS is
not delivered or is not as effective as in previous trials, then
cytisine may have lesser (or greater) impact. Secondly, the
study is not powered statistically to detect any differences
between the two arms for TB outcomes. However, we can
provide estimates for future research on TB outcomes by
quit status in the cohort. We will also use our data for a fu-
ture cumulative meta-analysis to ascertain effectiveness of
such interventions on TB outcomes.
Lastly, although cytisine has been used in eastern
Europe and in New Zealand, it has not been used in a study
in South Asia (tropical climate zone), and its stability and
pharmacovigilance have not been tested in the tempera-
tures and humidity encountered in this zone. Although
we will control the storage conditions of cytisine for the
study within the manufacturer’s recommended range,
there is a need for a pharmacovigilance study of cytisine
to establish its stability under different climatic conditions.
A placebo-controlled trial of cytisine raises some ques-
tions on the ethics of depriving at least 50% patients of a
treatment that has some good evidence of its efﬁcacy. Con-
versely, all trial participants are offered behaviour support
TB and Tobacco trial 9
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
with speciﬁc advice for patients on how to quit, with the
leaﬂet as an additional resource to take home. Besides, in
the current scenario, TB patients who smoke have almost
no chance of acquiring any smoking cessation medication;
in our trial they have at least a 50% chance. Furthermore,
the evidence on the efﬁcacy of cytisine is still not
completely established.
Retention and dropout is a key issue for all smoking ces-
sation trials. Nonetheless, we will ensure that, where possi-
ble, retention remains high. To our advantage, the trial
participants will have most of their follow-ups in line with
their routine TB treatment visits. However, higher attrition
rates are anticipated once TB treatment is completed. We
will set up follow-up reminders (text messages or phone
calls) and home visits for patients who are unable or un-
willing to visit the trial sites.
To summarize, if cytisine is found to be effective, it will
be an affordable option for policy makers in LMICs to
consider when including smoking cessation in TB
programmes.
Clinical trial registration
International Standard Randomized Clinical Trial Number
(ISRCTN43811467).
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